Abstract
Six patients with myoclonus of varying cause were treated with L-5-hydroxytryptophan (L-5-HTP) and carbidopa. While spontaneous myoclonus decreased in three of the patients and action myoclonus in four, only two patients had marked functional improvement. Side effects included gastrointestinal and affective disturbances. L-5-HTP therapy caused a diminished frequency of paroxysmal discharges in the electroencephalograms of three patients which did not always correlate with clinical improvement. Lumbar cerebrospinal fluid 5-hydroxyindoleacetic acid (5-HIAA) concentration after probenecid was decreased in all patients prior to therapy, but this reduction did not predict treatment response. Urinary excretion patterns for 5-HTP, serotonin, and 5-HIAA during treatment were similar in responders and nonresponders. It is concluded that while some patients with myoclonus do benefit from L-5-HTP therapy, biochemical and electrophysiological tests are not useful predictors of treatment response, and the high incidence of side effects limits the usefulness of this therapy.
References
Sep 6, 1975·Lancet·D ChadwickC D Marsden
Mar 1, 1978·Annals of Neurology·I RapinJ S O'Brien
Apr 1, 1978·Acta Neurologica Scandinavica·I MagnussenB de Fine Olivarius
Jan 13, 1977·The New England Journal of Medicine·M H Van WoertM B Bowers
Sep 1, 1977·Brain : a Journal of Neurology·D ChadwickC D Marsden
Dec 21, 1977·Biochemical and Biophysical Research Communications·J S O'Brien
Jul 1, 1978·Clinical Genetics·J S O'Brien
Mar 1, 1977·Epilepsia·J EngelD R Giblin
Jan 1, 1976·Neurology·M A Goldberb, J D Dorman
Feb 1, 1975·Neurology·M H Van Woert, V H Sethy
Sep 1, 1976·Neurology·J De LéanO Hornykiewicz
Dec 1, 1976·Neurology·J H GrowdonB T Shahani
Feb 6, 1976·Science·M AsbergV Ringberger
Jan 1, 1972·Psychopharmacologia·R Sjöström
Aug 1, 1970·The Journal of Pharmacy and Pharmacology·C V Atack, T Magnusson
Apr 1, 1973·Journal of the Neurological Sciences·C GuilleminaultD Cousin
Jan 1, 1972·Psychopharmacologia·H M van PraagT Schut
Mar 1, 1972·Clinica Chimica Acta; International Journal of Clinical Chemistry·N S SharplessC A Owen
Dec 10, 1971·Brain Research·J Korf, H M Van Praag
Mar 28, 1970·Nature·H M van PraagJ Puite
Mar 1, 1963·Brain : a Journal of Neurology·J W LANCE, R D ADAMS
Citations
Feb 1, 1995·Annals of Neurology·M R PranzatelliK Banasiak
Sep 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·R R MatsumotoD D Truong
Nov 30, 2000·Current Treatment Options in Neurology·S Frucht
Jun 27, 2008·Current Treatment Options in Neurology·Victoria C Chang, Steven J Frucht
Apr 1, 1995·Pharmacology, Biochemistry, and Behavior·R R MatsumotoD D Truong
Jul 3, 1998·European Journal of Pharmacology·E J PappertP M Carvey
Jul 1, 1996·Mayo Clinic Proceedings·J N Caviness
Sep 5, 2001·Neurologic Clinics·K Blindauer
Aug 1, 1995·Epilepsia·M R PranzatelliD Franz
Mar 1, 1990·Epilepsia·M GiroudJ Bralet
Dec 1, 1985·Journal of Neurology, Neurosurgery, and Psychiatry·J A ObesoJ M Martínez Lage
Oct 1, 1985·The Journal of Clinical Investigation·Y ShenkerR J Grekin
Jan 1, 1985·Annals of the New York Academy of Sciences·L J Thal
Jan 1, 1983·International Journal of Psychiatry in Medicine·R L Goldberg
Sep 1, 1989·Medical Hypotheses·M R Pranzatelli
Mar 14, 2020·Pharmacology Research & Perspectives·Zheng GuanWei Zhao
Jan 1, 1986·Suicide & Life-threatening Behavior·H M van Praag
Jun 30, 2018·Current Neuropharmacology·Faheem Hyder PottooMohammad Azam Ansari